AR132189A1 - Método para la producción de preparados de partículas de aav recombinantes - Google Patents
Método para la producción de preparados de partículas de aav recombinantesInfo
- Publication number
- AR132189A1 AR132189A1 ARP240100694A ARP240100694A AR132189A1 AR 132189 A1 AR132189 A1 AR 132189A1 AR P240100694 A ARP240100694 A AR P240100694A AR P240100694 A ARP240100694 A AR P240100694A AR 132189 A1 AR132189 A1 AR 132189A1
- Authority
- AR
- Argentina
- Prior art keywords
- adeno
- gene
- raavp
- culturing
- associated virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
- C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En la presente se informa un método para producir un preparado de partículas virales adenoasociadas recombinantes (rAAVp) que comprende la etapa de cultivar una célula de mamífero que comprende casetes de expresión para un gen viral no adenoasociado, que está interespaciado entre dos repeticiones terminales invertidas (ITR) de AAV, un gen rep de virus adenoasociado, un gen cap de virus adenoasociado, un gen E1A de virus adenoasociado, un gen E1B de virus adenoasociado, un gen E2A de virus adenoasociado, un E4orf6 de virus adenoasociado y un gen ARN VA de virus adenoasociado, y producir así el rAAVp, en donde el cultivo es a un valor de pH en el rango de y que incluye pH 7,4 a pH 7,6. El rendimiento del rAAVp producido mediante el cultivo a un valor de pH en el rango de y que incluye pH 7,4 a pH 7,6 es mayor que el rendimiento de un rAAVp producido mediante un cultivo a un valor de pH en el rango de y que incluye pH 7,0 a pH 7,2 y el rAAVp producido mediante el cultivo a un valor de pH en el rango de y que incluye pH 7,4 a pH 7,6 tiene un porcentaje mayor de partículas completas que un rAAVp producido mediante un cultivo a un valor de pH en el rango de y que incluye pH 7,0 a pH 7,2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23163162 | 2023-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132189A1 true AR132189A1 (es) | 2025-06-04 |
Family
ID=85724795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100694A AR132189A1 (es) | 2023-03-21 | 2024-03-21 | Método para la producción de preparados de partículas de aav recombinantes |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20260139234A1 (es) |
| EP (1) | EP4683676A1 (es) |
| JP (1) | JP2026511015A (es) |
| KR (1) | KR20250162543A (es) |
| CN (1) | CN120835797A (es) |
| AR (1) | AR132189A1 (es) |
| AU (1) | AU2024239386A1 (es) |
| IL (1) | IL323167A (es) |
| MX (1) | MX2025010665A (es) |
| TW (1) | TW202503065A (es) |
| WO (1) | WO2024194280A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026085229A1 (en) * | 2024-10-16 | 2026-04-23 | Genzyme Corporation | Methods and compositions for raav production |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US6093699A (en) | 1987-07-09 | 2000-07-25 | The University Of Manitoba | Method for gene therapy involving suppression of an immune response |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| WO1994017810A1 (en) | 1993-02-12 | 1994-08-18 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| WO1994023744A1 (en) | 1993-04-16 | 1994-10-27 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6100242A (en) | 1995-02-28 | 2000-08-08 | The Regents Of The University Of California | Gene therapies for enhancing cardiac function |
| US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
| US6004797A (en) | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
| US6228646B1 (en) | 1996-03-07 | 2001-05-08 | The Regents Of The University Of California | Helper-free, totally defective adenovirus for gene therapy |
| WO2000014205A2 (en) | 1998-09-04 | 2000-03-16 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant aav vectors |
| CA2995542A1 (en) | 1997-09-05 | 1999-03-11 | Genzyme Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| US6593123B1 (en) | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
| JP4559429B2 (ja) | 2003-05-21 | 2010-10-06 | ジェンザイム・コーポレーション | 空キャプシドを実質的に含まない組換えaavビリオン調製物を生成するための方法 |
| DE102005054628A1 (de) | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
| EP2529020B1 (en) | 2010-01-28 | 2018-04-25 | The Children's Hospital of Philadelphia | A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy |
| EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| JP6342886B2 (ja) | 2012-04-18 | 2018-06-13 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | Aavカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法 |
| NZ716102A (en) | 2013-07-22 | 2021-12-24 | The Children’S Hospital Of Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
| EP3384015A4 (en) | 2015-12-01 | 2019-05-29 | Spark Therapeutics, Inc. | SCALABLE PROCESS FOR THE PREPARATION OF A RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR IN A SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR THE CLINICAL APPLICATION |
| WO2018226887A1 (en) | 2017-06-07 | 2018-12-13 | Spark Therapeutics, Inc. | ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION |
| EP3658250A4 (en) | 2017-06-30 | 2021-10-27 | Spark Therapeutics, Inc. | AAV VECTOR COLUMN CLEANING PROCEDURE |
| EP4585229A3 (en) | 2017-11-08 | 2026-01-14 | Novartis AG | Means and method for preparing viral vectors and uses of same |
-
2024
- 2024-03-19 WO PCT/EP2024/057207 patent/WO2024194280A1/en not_active Ceased
- 2024-03-19 JP JP2025555174A patent/JP2026511015A/ja active Pending
- 2024-03-19 CN CN202480020036.8A patent/CN120835797A/zh active Pending
- 2024-03-19 KR KR1020257030243A patent/KR20250162543A/ko active Pending
- 2024-03-19 AU AU2024239386A patent/AU2024239386A1/en active Pending
- 2024-03-19 EP EP24711897.9A patent/EP4683676A1/en active Pending
- 2024-03-20 TW TW113110368A patent/TW202503065A/zh unknown
- 2024-03-21 AR ARP240100694A patent/AR132189A1/es unknown
-
2025
- 2025-09-04 IL IL323167A patent/IL323167A/en unknown
- 2025-09-10 MX MX2025010665A patent/MX2025010665A/es unknown
- 2025-09-17 US US19/331,653 patent/US20260139234A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025010665A (es) | 2025-10-01 |
| KR20250162543A (ko) | 2025-11-18 |
| IL323167A (en) | 2025-11-01 |
| WO2024194280A1 (en) | 2024-09-26 |
| TW202503065A (zh) | 2025-01-16 |
| AU2024239386A1 (en) | 2025-08-14 |
| EP4683676A1 (en) | 2026-01-28 |
| CN120835797A (zh) | 2025-10-24 |
| JP2026511015A (ja) | 2026-04-10 |
| US20260139234A1 (en) | 2026-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aponte-Ubillus et al. | Molecular design for recombinant adeno-associated virus (rAAV) vector production | |
| AU2023200992B2 (en) | Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use | |
| US12466858B2 (en) | Helper plasmid and method for preparing recombinant adeno-associated virus | |
| US20190321463A1 (en) | Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy | |
| Qiao et al. | Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes | |
| CN115997006A (zh) | 用于产生aav的双双功能载体 | |
| JP2022507534A5 (es) | ||
| MX2025010665A (es) | Metodo para la produccion de preparaciones de particulas virales adenoasociadas (aav) recombinantes | |
| JP2009195237A5 (es) | ||
| WO2022116285A1 (zh) | 一种重组腺相关病毒的制备方法、系统及重组杆粒 | |
| Wang et al. | A robust system for production of superabundant VP1 recombinant AAV vectors | |
| Yamaji et al. | Efficient production of Japanese encephalitis virus-like particles by recombinant lepidopteran insect cells | |
| Wang et al. | Establishment of a scalable manufacturing platform for in-silico-derived ancestral adeno-associated virus vectors | |
| US20100323429A1 (en) | Methods for purifying baculovirus | |
| Zhang et al. | Improvement of protein production by engineering a novel antiapoptotic baculovirus vector to suppress the expression of Sf‐caspase‐1 and Tn‐caspase‐1 | |
| AR123777A1 (es) | Constructos de ácido nucleico para transcripción de arn va | |
| Keith et al. | Screening of transformed insect cell lines for recombinant protein production | |
| MX2024002379A (es) | Cápsides y vectores de aav modificados. | |
| TWI510625B (zh) | 至少可感染三種昆蟲宿主之雜合桿狀病毒及其用途 | |
| JP2023546116A5 (es) | ||
| WO2025209979A1 (en) | METHOD FOR PRODUCING RECOMBINANT VIRUSES OR VIRUS-LIKE PARTICLES (VLPs) IN MAMMALIAN CELL LINES | |
| MX2024009778A (es) | Producción de virus de la estomatitis vesicular recombinante de alto título en cultivo celular en suspensión | |
| Huang et al. | Homologous recombination risk in baculovirus expression vector system | |
| Pei et al. | Enhancement of exogenous protein stability in AcMNPV by overexpressing lef5 gene during passaging | |
| RU2025128274A (ru) | Способ получения препаратов частиц рекомбинантного aav |